Explore the vast range of titles available.

Background Adverse food reactions (AFR) are a common cause of skin diseases in dogs, with a prevalence of up to 24%. Research in humans and mice has shown that a high intake of vegetable oils rich in omega-6 polyunsaturated fatty acids (n-6 PUFA) can increase the risk and severity of allergic diseases. This study aimed to investigate the association between AFR and the supplementation of vegetable oils in the canine diet. Results A total of 459 dogs were analyzed, with atopic dermatitis (22.66%) and adverse food reactions (AFR) (8.06%) being the most common diagnoses. Oil supplementation was recorded in 14.16% of dogs, with extra-virgin olive oil being the most common (70.77%). Dogs with AFR and concurrent AFR and CAD showed significantly higher oil supplementation rates compared to other conditions ( P  < 0.05; P  < 0.001). No significant association was found between oil type and diagnosis ( P  = 0.563). After excluding EFA-supplemented dogs and those on prescription dermo diets, oil supplementation was still more prevalent in dogs with AFR compared to other conditions (29.31% vs. 10.10%, P  < 0.001). Conclusions Vegetable oil supplementation was more frequent in dogs with AFR than in those with other dermatological conditions. This is the first study to evaluate the relationship between vegetable oil supplementation and AFR in dogs. While vegetable oil supplementation is associated with AFR, further studies are needed to establish causality and better understand the role of n-6 PUFA in the development of food allergies in dogs.

Background: Intralymphatic immunotherapy (ILIT) has been used successfully in both human and veterinary medicine as a safe and effective treatment for allergic diseases. Initially, ILIT was administered by ultrasound guidance, but palpation-based injections have become more popular among veterinary dermatologists. Data from human medicine, however, show that precise injection into the lymph node is mandatory, and injection quality clearly correlates with clinical response. Hypothesis: Our aim was to assess the impact of the injection method (ultrasound guidance versus palpation-based guidance) on clinical response in dogs with atopic dermatitis. Methods: A total of 129 canine atopic dermatitis (CAD) cases treated with ILIT between 2014 and 2022 were retrieved from the hospital clinical database. The included dogs had to receive at least three intralymphatic injections administered either by palpation or ultrasound guidance. Those cases were retrospectively assessed and compared regarding clinical response to ILIT. Results: In total, 84 dogs received ILIT by ultrasound guidance, and in 25 dogs, ILIT was injected based on palpation. The success rate of ILIT was significantly higher in the ultrasound guidance group when compared to palpation-based injections. Conclusions: Low-quality injections must be considered as a possible reason for ILIT failure in dogs. Further prospective and controlled studies are necessary to confirm these results.

There is no established protocol for the development of an experimental canine atopic dermatitis model in laboratory beagles. This study aimed to establish an experimental model that mimics spontaneous canine atopic dermatitis (CAD) clinically, immunologically, and microbiologically, by repeated epicutaneous applications of mite antigens and to describe the entire process including sensitization and provocation in detail for reproducibility. Six intact male laboratory beagle dogs aged 14 months were included in this study. During the sensitization and provocation phase, the house dust mite (HDM) paste consisted of Dermatophagoides farinae ( Der f ) and mineral oil, which was applied focally to the 10 × 10 cm area of the right groin as evenly as possible. Further, 120 mg of Der f was applied to each dog twice a week for 12 weeks during the sensitization phase and 25 mg and 120 mg was applied to each dog for the first 2 weeks and subsequent 2 weeks, respectively, during the provocation phase. Thereafter, the applied area was covered with a dressing. Skin lesions including erythema, hyperpigmentation, excoriation, and lichenification were induced and exacerbated gradually through the experimental time course in all six dogs. The canine atopic dermatitis extent and severity index (CADESI) score and transepidermal water loss (TEWL) significantly increased after sensitization and provocation. IL-13 and IL-31 levels increased significantly after provocation as a result of the activation of the T helper-2 (Th2) response. On the contrary, the IL-10 levels decreased significantly after sensitization, which suggested a suppression of Tregs activity. After the completion of provocation, skin microbiome analysis showed that Firmicutes was the most abundant phylum, which indicated bacterial dysbiosis. This study demonstrated that epicutaneous application of HDM in beagle dogs resulted in the elevation of serum HDM-specific IgE levels and clinical atopic scores, a high TEWL, and microbiome dysbiosis resembling spontaneous CAD. These results suggest that this tailored protocol of epicutaneous exposure to Der f may provide support for the development of the experimental CAD model in laboratory beagles.

The management of canine atopic dermatitis, an allergic skin disorder, is challenging. To investigate the effect of phototherapy using a 308-nm excimer light as a topical treatment for canine atopic dermatitis, 10 dogs with canine atopic dermatitis and 10 with non-allergic skin were enrolled in this study. Phototherapy was applied every 7 days for a total of 2 months. The skin microbiome, skin barrier function, and clinical outcomes were evaluated after phototherapy. Phototherapy significantly changed the composition of the skin microbiome of dogs with atopic dermatitis and significantly increased the relative abundance of the phyla Actinobacteria and Cyanobacteria. It significantly alleviated the clinical signs of canine atopic dermatitis without serious adverse effects. Transepidermal water loss, as a measure of skin barrier function, significantly decreased after phototherapy. In addition, phototherapy increased microbial diversity and decreased the relative abundance of Staphylococcus pseudintermedius associated with the severity of canine atopic dermatitis. These results suggest that the excimer light therapy is a suitable and safe therapeutic option for canine atopic dermatitis, which is also a spontaneous animal model of atopic dermatitis.

Canine atopic dermatitis (cAD) is a common allergic skin condition among dogs that may respond to treatment with mesenchymal stromal cells (MSCs). The aim of this pilot study was to evaluate the safety and efficacy of allogeneic uterine tissue-derived MSCs (UMSCs) for the reduction and control of clinical signs associated with cAD. At two sites, seven client-owned dogs with cAD received two doses of approximately 3.6 x 10 7 UMSCs given intravenously over 30 min, on Day 0 and Day 14, with monthly clinical follow-up until Day 90 and optional owner phone interview on Day 180. Primary outcomes were pruritus and skin lesions. Pruritus was measured by the owner-assessed Pruritus Visual Analog Scale (PVAS), with treatment success defined as a 2-point reduction in PVAS score at any timepoint after treatment. Skin lesions were evaluated by two veterinarians according to the Canine Atopic Dermatitis Extent and Severity Index (CADESI-4). The secondary outcome was safety, which was evaluated via physical exam and hematology, including complete blood count (CBC), serum chemistry, and urinalysis (UA). Treatment was generally well tolerated and associated with a significant reduction in PVAS on Day 30 that was maintained through Day 180. On Day 60, five dogs (71%) achieved treatment success (at least 2-point reduction in PVAS), and three dogs (43%) had a PVAS improvement of 4-5 points. Mean CADESI-4 score was significantly improved on Day 14, Day 30, Day 60, and Day 90, with the lowest mean score observed on Day 60. Three dogs exhibited mild and transient adverse events. These findings suggest that IV-administered allogeneic UMSCs reduce and control clinical signs of cAD, with a durable benefit lasting 3–6 months.

Both humans and their most important domestic animals harbor IgE and a similar IgE receptor repertoire and expression pattern. The same cell types are also involved in the triggering or regulation of allergies, such as mast cells, eosinophils or T-regulatory cells. Translational clinical studies in domestic animals could therefore help cure animal allergies and at the same time gather knowledge relevant to human patients. Dogs, cats and horses may spontaneously and to different extents develop immediate type symptoms to pollen allergens. The skin, nasal and bronchial reactions, as well as chronic skin lesions due to pollen are in principle comparable to human patients. Pollen of various species most often causes allergic rhinitis in human patients, whereas in dogs it elicits predominantly eczematous lesions (canine atopic dermatitis), in horses recurrent airway obstruction or hives as well as pruritic dermatitis, and in cats bronchial asthma and so-called cutaneous reactive patterns (eosinophilic granuloma complex, head and neck pruritus, symmetric self-induced alopecia). In human allergy-specific IgE detection, skin tests or other allergen provocation tests should be completed. In contrast, in animals IgE and dermal tests are regarded as equally important and may even replace each other. However, for practical and economic reasons intradermal tests are most commonly performed in a specialized practice. As in humans, in dogs, cats and horses allergen immunotherapy leads to significant improvement of the clinical symptoms. The collected evidence suggests that canines, felines and equines, with their spontaneous allergies, are attractive model patients for translational studies.

Treatment approaches to canine atopic dermatitis (CAD) must be individualized and flexible, must combine several modes of therapy, and must be aimed at both the primary disease and at secondary complications. This chapter discusses the elements of successful treatment plans and how these elements are best combined for different clinical situations. Wherever possible stress should be on a proactive approach to treatment—in other words, correcting the underlying pathogenesis of the disease where possible, preventing acute flares where we can, and forestalling the development of chronic inflammatory changes in the skin that become much more difficult to reverse. The development of ‘Practice Guidelines’ is a newer concept that applies principles of evidence‐based medicine to treatment of the most common clinical patient presentations, providing practical recommendations to assist clinicians in choosing effective treatment protocols.

In veterinary dermatology, cutaneous adverse food reaction (CAFR) and canine atopic dermatitis (CAD) have been historically considered as two different conditions. CAFR includes both immune‐mediated and non‐immune‐mediated food intolerances and may be associated with a wide range of clinical signs. The clinical signs of CAD may be associated with sensitization to environmental (CAD sensu stricto) or food allergens. This chapter describes the clinical features of dogs affected by CAD from whatever cause. Clinical signs of CAD may be seasonal or not; seasonality is often present at onset (42‐75%). Some dogs with non‐seasonal disease can exhibit worsening of clinical signs during one specific season. Although common, CAD may be difficult to diagnose owing to the lack of pathognomonic signs and the protean clinical signs. Erythema and pruritus are virtually always present and often represent the first clinical signs. The chapter illustrates the breed‐associated phenotypic variability of CAD.

Historically, canine atopic dermatitis (CAD) was first described in dogs allergic to ragweed pollens. These descriptions led to the definition of atopic dermatitis as a pruritic dermatitis due to allergy to environmental allergens. These allergens include dust and storage mites, pollens, mould spores, epithelium, insects, and antigens like kapok or wool. Environmental allergens still play a major role in most cases, but the improved knowledge on the specificity of the immune response to these allergens has allowed a more targeted diagnostic approach. Cross‐sensitization to environmental allergens is predominantly to house dust mites (HDM) in atopic dogs. Standardization of allergenic extracts adapted to each species (human, dog, cat, horse) could allow the production of more efficient allergenic extracts for the diagnosis and treatment of atopic dermatitis. Furthermore, this would enable a big step forward in clinical and basic science research of CAD.

For the diagnosis of canine atopic dermatitis (CAD), it is important to determine if the pruritus and erythema observed are the result of environmental CAD, and/or presence of hypersensitivity to fleas, and/or adverse reaction to food, and/or of infections. The main differential diagnosis of atopic dermatitis is adverse food reaction. This chapter provides a list of differential diagnoses for causes of chronic pruritus, in a tabular form. A complete diagnosis of CAD involves identifying and treating complicating infections and other factors and determining what signs reflect the uncomplicated case of CAD. Diet trials, aggressive flea control, cytology and appropriate antibiotic or antiyeast agents, used alone or in combination, are often required to really determine how CAD manifests in a given patient.